Santa Ana Bio Advances SAB01 Into Phase 1
ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...
Precision Immunology
Advertisement
Boulevard Bio Launches with $65M to Advance Immunology
NEW YORK, New York, August 12, 2026 Boulevard Bio has emerged from stealth with approximately $65 million in financing...
Gazyva Phase III Success in Autoimmune Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2026 — Genentech announced positive Phase III clinical trial results showing that Gazyva®...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Advertisement
